Challenges facing health professionals caring for HIV-infected drug users

AIDS Patient Care and STDs

Volumn 17, Issue 7, 2003, Pages 333-343

  Inungu, Joseph ^a   Beach, Eileen Malone ^a   Skeel, Reid ^a  

^a CENTRAL MICHIGAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; ILLICIT DRUG; METHADONE; NEUROLEPTIC AGENT; NEVIRAPINE; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

BEHAVIOR MODIFICATION; DRUG ABUSE; GASTROINTESTINAL SYMPTOM; HEALTH PRACTITIONER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LIVER TOXICITY; MENTAL DISEASE; MODEL; PATIENT CARE; RASH; REVIEW; SOCIAL LEARNING;

ANTI-RETROVIRAL AGENTS; BEHAVIOR THERAPY; HEALTH BEHAVIOR; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 0041808720     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729103322231277     Document Type: Review

References (102)

1. UNAIDS. Report on the Global HIV/AIDS Epidemic, June 2000.
2. Centers for Disease Control. HIV/AIDS Surveillance Report. Midyear 2001 edition, Volume 13, Number 1.
3. Stein MD, Rich JD, Maksad J, et al. Adherence to Antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000;26:195-205.
4. SAMHA. National Household Survey on Drug Abuse Report. 2001 Online document at: www.samhsa.gov/ oas/NHSDA/2k1NHSDA/voll/Chapter2.htm
5. Leshner A. Understanding drug addiction: implications for treatment. Hosp Pract (Off Ed). 1996;31: 47-54.
6. Centers for Disease Control. Policy issues and challenges in substance abuse treatment. Substance Abuse Treatment Fact Sheets, February 2001.
7. Stone VE, Mansourati FF, Poses RM, Mayer KH. Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy. J Gen Intern Med 2001;16:360-368.
8. McLaughlin D, Long A. An extended literature review of health professionals' perception of illicit drugs and their clients who use them. J Psychiatr Ment Health Nurs 1996;3:283-288.
9. Howard MO, Chung SS. Nurses' attitudes toward substance misusers. III. Emergency room nurses' attitudes, nurses' attitudes toward impaired nurses, and studies of attitudinal change. Subst Use Misuse 2000;35:1227-1261.
10. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):S5-14.
11. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
12. Metsch LR, Penyra M, Brewer TH. Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. J Subst Abuse 2001;13:155-167.
13. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15: 1707-1715.
14. Roca B, Gomez CJ, Arnedo A. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: Adherence, side effects and efficacy. J Infect 1999;39:141-145.
15. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: Breakthroughs and barriers. AIDS Care 2002;14:309-318.
16. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001;27:251-259.
17. Stein MD, Rich JD, Maksad J, Chen MH, Hu P, Sobota M, Clarke J. Adherence to antiretroviral therapy among HIV-infected methadone patients: Effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000;26:195-205.
18. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000;14:151-155.
19. Hextall R, Monteiro EF. Re-audit of antiretroviral prescribing in HIV patients. Int J STD AIDS 2001; 12:398-399.
20. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 2000;50:1599-1605.
21. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus infected patients. J Infect Dis 2002;185(Suppl 2):S143-151.
22. Avants SK, Margolin A, Warburton LA, Hawkins KA, Shi J. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addiction 2001;10:69-78.
23. Bogart LM, Catz SL, Kelly JA, Benotsch EG. Factors influencing physicians' judgments of adherence and treatment decisions for patients with HIV disease. Med Decis Making 2001;21:28-36.
24. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factor on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr 2000;23:396-404.
25. Murri R, Fantoni M, Del Borgo C, et al. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr 1999;22:461-466.
26. Maisels L, Steinberg J, Tobias C. An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDS 2001;15:185-191.
27. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999;21:114-119.
28. Kilby M, Hill AM, Buss N. The effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of 120 subjects [abstract 1650]. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario, Canada; September 17-20, 2000.
29. Michalets EL. Update: Clinically significant cytochrome p-450 drug interactions. Pharmacotherapy 1998;18:84-112.
30. Piscitelli S. Preventing dangerous drug interactions. Platform presentation of the American Pharmaceutical Association Annual Meeting: March 10-14, 2000, Washington, D.C.
31. Gerber JG, Gal J, Rosenkranz S, et al., for the ACTG 401 Study Team. The effect of ritonavir/saquinavir on the selective pharmacokinetics of methadone [Abstract WePeB 4211]. Program and Abstract of the XIII International AIDS Conference, July 9-14, 2000. Durban, South Africa.
32. Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000;24:241-248.
33. Clarke SM, Mulcahy FM. Antiretroviral therapy for drug users. Int J STD AIDS 2000;11:627-631.
34. Timour K, Staten Island AIDS Task Force. Recreational drugs, methadone and protease inhibitors. The Body: An AIDS and HIV information resource 1998, volume XI, no4/5. Online document at: www. thebody.com/bp/aprmay98/rec_drugs.html
35. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999; 159:2221-2224.
36. Sension MG, Farthing C, Shaffer AG, Graham E, Siemon-Hryczk P, Pilson RS. Challenges of Antiretroviral treatment in transient and drug-using populations: The SUN study. AIDS Patient Care STDs 2001;15:129-136.
37. Yasuoka A. Challenges of the anti-retroviral therapy. Nippon Rinsho 2002;60:750-756.
38. Brouwers P, DeCarli C, Tudor-Williams G, Civitello L, Moss H, Pizzo P. Interrelations among patterns of change in neurocognitive, CT brain imaging and CD4 measures associated with antiretroviral therapy in children with symptomatic HIV infection. Adv Neuroimmunol 1994;4:223-231.
39. Antinoni A, Baldwin F, Girardi E, et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001;15:1579-1581.
40. Prakash M, Poreddy V, Tiyyagwa L, Bonacini M. Jaundice and hepatocellular damage associated with nevirapine therapy. Am J Gastroenterol 2001;96:1571-1574.
41. Mason CJ, Greenfield SM, Turner JL. Acute pancreatic as a common complication of 2′3′dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992;87:708-713.
42. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati VD. Adefovir nephrotoxicity: Possible role of mitochondria DNA depletion. Hum Pathol 2001;32:734-740.
43. Arranz Caso JA, Sanchez Mingo C, Garcia Tena J. Effect of highly active antiretroviral therapy on thrombocytopenia in patients with HIV infection. N Engl J Med 1999;341:1239-1240.
44. Smith KY. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J Infect Dis 2002;185:S123-127.
45. Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials 2002;3:89-98.
46. Highleyman L. Side effects associated with anti-HIV drugs. BETA 1998;22:13-18.
47. Lucas GM, Cheever LM, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001;27:251-259.
48. Serano V, Sulkowski M, Bergin C, et al. Editorial review. Care of patient with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. AIDS 2002;16:813-828.
49. Monts A. Hepatitis C and steatosis. Semin Gastrointest Dis 2002;13:40-46.
50. Dore GJ, Cooper DA. The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Curr Opin Infect Dis 2001;14:749-755.
51. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002;34: 1259-1263.
52. Rosenberg PM, Farrell JJ, Abraczinskas DR, Graeme-Cook FM, Dienstag JL, Chung RT. Rapidly progressive fibrosing cholestatic hepatistis. Hepatitis C virus in HIV coinfection. Am J Gastroentrol 2002;97: 478-483.
53. Drug Stove News. A common sense approach to drug interactions. Accessed on August 30, 1999. Online document at: wwwfindarticles.com/cfdls/m3374/ 13_21/55693815/p1/article.jhtml
54. Fernandez I, Rubio R, Lumreras C. Hepatitis C in HIV-infected patients - Therapeutic approach. Clin Microbiol Infect 2002;8:80-84.
55. National Coalition for Effective Drug Policies, Washington, D.C. Eight Steps to Effectively Controlling Drug Abuse And the Drug Market. Online document at: www.csdp.org/news/news/8steps.htm
56. Cummings KM, Jette AM, Rosenstock IM. Construct validation of the health belief model. Health Educ Monogr 1978 Winter;6:394-405.
57. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the health belief model. Health Educ Q 1988;15:175-183.
58. Mississippi State University. Health education behavior models and theories: - A review of the literature - part I. Online document at: msucares.com/ health/health/appa1.htm
59. Nigg CR, Burbank P, Padula C, et al. Stages of change across ten health risk behaviors for older adults. Gerontologist 1999;39:473-482.
60. Cecil H, Pinkerton SD. Reliability and validity of a self-efficacy instrument for protective sexual behaviors. J Am Coll Health 1998;47:113-121.
61. Silver WS, Mitchell TR, Gist ME. Responses to successful and unsuccessful performance: The moderating effect of self-efficacy on the relationship between performance and attributions. Organ Behav Hum Decis Proc 1995;62:286-299.
62. Larimer ME, Palmer RS, Marlett GA. Relapse prevention: an overview of Marlatt's cognitive-behavioral model. Alcohol Res Health 1999;23:151-160.
63. Ajzen I. Attitude, traits, and actions: dispositional prediction of behavior in personality and social psychology. Adv Exp Soc Psych 1987;20:1-63.
64. Pende NJ, Pende AR. Attitudes, subjective norms and intentions to engage in health behavior. Nurs Res 1986;35:15-18.
65. Glanz K, Lewis RM, Rimer BK, eds. Health Behavior and Health Education: Theory, Research, and Practice. San Francisco: Jossey-Bass, 1990.
66. Verplanken B, Aarts H, van Knippenberg, Moonen A. Habit versus planned behaviour: A field experiment. Br J Soc Psychol 1998;37:111-128.
67. Bandura A. Social Foundations of Thought and Action. Englewood Cliffs, NJ: Prentice-Hall, 1986.
68. Clark MM, Pera V, Goldstein MG, Thebarge RW, Guise BJ. Counseling strategies for obese patients. Am J Prev Med 1996;12:266-270.
69. Elder JP, Ayala GX, Harris S. Theories and intervention approaches to health-behavior change in primary care. Am J Prev Med 1999;17:275-284.
70. Zarit SH, Orr NK, Zarit JM. The Hidden Victims of Alzheimer's Disease: Families Under Stress. New York, NY: New York University Press, 1985.
71. Proshaska JO and DiClemte CC. Stages of change in the modification of problem behaviors. Prog Behav Modif 1992;28:183-218.
72. Rosen CS. Is the sequencing of change processes by stage consistent across health problems? A meta-analysis. Health Psychol 2000;19:593-604.
73. Pattern S, Vollman A, Thurston W. The utility of the Transtheoretical model of behavior change for HIV risk reduction in injection users. J Assoc Nurses AIDS Care 2000;11:57-66.
74. Rollnick S, Heather N, Bell A. Negotiating behavior change in medical settings: The development of brief motivational interviewing. J Mental Health 1992; 1:25-37.
75. Resnicow K, DiIorio C, Soet JE, Borrelli B, Hecht J, Ernst D. Motivational interviewing in health promotion: it sounds like something is changing. Health Psychol 2002;21:444-451.
76. Fisher D. Communication in Organizations, 2nd ed. St. Paul: West, 1993.
77. Butler C, Rollnick S, Cohen D, Bachman M, Russell I, Stott N. Motivational consulting versus brief advice for smokers in general practice: a randomized trial. Br J Gen Pract 1999;49:611-616.
78. Turner BJ, Zhang D, Laine C, Pomerantz, Cosler L, Hauck WW. Association of provider and Patient Characteristics with HIV-infected Women's antiretroviral therapy regimen. J Acquir Immune Defic Syndr 2001;27:20-29.
79. Pradier C, Carrieri P, Bentz L, et al. Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDUs. Int J STD AIDS 2001;12:324-328.
80. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002;12: 305-307, 312-316.
81. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health 1999;76:468-480.
82. Bangsberg DR, Hecht FM, Clague H, et al. Provider Assessment of Adherence to HIV Antiretroviral Therapy. J Acquir Immune Defic Syndr 2002;26: 435-442.
83. Gregory M. Lucas. Management of HIV Infection in Injection-Drug Users. HIV/AIDS: Annual Update 2001. Online document at: www.medscape.com/ viewarticle/418652_print
84. Steele RG, Anderson B, Rindel B, et al. Adherence to antiretroviral therapy among HIV-positive children: Examination of the role of caregiver health beliefs. AIDS Care 2001;13:617-629.
85. Adih WK, Alexander CS. Determinants of condom use to prevent HIV infection among youth in Ghana. J Adolesc Health 1999;24:63-72.
86. Steers WN, Elliott E, Nemiro J, Ditman D, Oskamp S. Health beliefs as predictors of HIV-preventive behavior and ethnic differences in prediction. J Soc Psychol 1996;136:99-110.
87. Yep GA. HIV prevention among Asian-American college students: does the health belief model work? J Am Coll Health 1993;41:199-205.
88. Abraham C, Sheeran P, Spears R, Abrams D. Health beliefs and promotion of HIV-preventive intentions among teenagers: a Scottish perspective. Health Psychol 1992;11:363-370.
89. Bosompra K. Psychosocial determinants of condom use among Ghanaian students: An application of the theory of planned behavior and the health belief model. Diss Abstr Int 1999;59(10-B):5327.
90. Gagnon MP, Godin G. The impact of new antiretroviral treatments on college students' intention to use a condom with a new sexual partner. AIDS Educ Prev 2000;12:239-251.
91. Jemmott JB III, Jemmott LS, Hacker CI. Predicting intentions to use condoms among African-American adolescents: The theory of planned behavior as a model of HIV risk-associated behavior. Ethn Dis 1992;2:371-380.
92. Dilorio C, Dudley WN, Soet J, Watkins J, Maibach E. A social cognitive-based model for condom use among college students. Nurs Res 2000;49:208-214.
93. Raj A. Identification of social cognitive variables as predictors of safer sex behavior and intent in heterosexual college students. J Sex Marital Ther 1996; 22:247-258.
94. Prochaska JO, Redding CA, Harlow LL, Rossi JS, Velicer WF. The transtheoretical model of change and HIV prevention: A review. Health Educ Q 1994; 21:471-486.
95. Konkle-Parker DJ. A motivational intervention to improve adherence to treatment of chronic disease. J Am Acad Nurse Pract 2001;13:61-68.
96. Parsons JT, Huszti HC, Crudder SO, Rich L, Mendoza J. Maintenance of safer sexual behaviours: evaluation of a theory-based intervention for HIV seropositive men with haemophilia and their female partners. Haemophilia 2000;6:181-190.
97. Patten S, Vollman A, Thurston W. The utility of the Transtheoretical Model of behavior change for HIV risk reduction in injection drug users. J Assoc Nurses AIDS Care 2000;11:57-66.
98. Jamner MS, Wolitski RJ, Corby NH. Impact of a longitudinal community HIV intervention targeting injecting drug users' stage of change for condom and bleach use. Am J Health Promot 1997;12:15-24.
99. US Food and Drug Administration National Consumers Leagues. 1998. Food Drug Interactions Online document at: vm.cfsan.fda.gov/~lrd/fdinter.html
100. Pronsky ZM. HIV medications-food interactions handbook. Online document at: www.foodmed interactions.com/hivinfo.html
101. American Family Physician. Clinically significant drug interactions. Accessed March 15, 2000. Online document at: wwwfindarticles.com/cfdls/m3225/ 661/61432829/p1/article/jhtml
102. Flexner C. Pharmacology and drug interactions. 2000. Online document at: www.medscape.com/ viewarticle/418958